Table 3 Published clinical trials of CAR-T therapy for T-ALL and T-LBL at the 2021 ASH annual meeting
Clinical trials (reference) | ChiCTR2000034762 [110] | Abstract 473 [53] | Abstract 652 [54] | RD13-01 [111] | Abstract 654 [57] |
|---|---|---|---|---|---|
Phase | Phase 1 | Phase 1 | Phase 1 | Phase 1 | Phase 1 |
Diseases | CD7-positive R/R T-ALL | R/R T-ALL | R/R T-LBL | R/R CD7+ hematological malignancies | R/R mature T-cell lymphoma |
Target | CD7 | CD7 | CD7 | CD7 | CD5 |
Cell source | Stem-cell transplantation donors or new donors | Autologous | Autologous (7/8) or donor (1/8) | Universal CAR-T cells | Autologous |
Patients (n) | 20 | 17 | 8 | 11 | 9 |
Median of prior lines of therapies | 3 | 5 | 5 | NA | 5 |
Prior HSCT | 35% | 17.6% | 25% | 25% | 55.6% |
Follow-up time | Median 6.3 months | Median 105 days | Median 93 days | Median 100 days | NA |
Response rate (ORR/CR) | ORR: 95% CR: 90% | CR/CRi: 92.9% | CR/CRi: 62.5% | ORR: 82% CR (leukemia): 75% CR (T-NHL): 33.3% | ORR: 44.4% CR: 22.2% |
CRS, any grade | 100% | 100% | 100% | 83.3% | 44.4% |
ICANS, any grade | 15% | 5.9% | 12.5% | 0 | 11.1% |
Grade ≥ 3 neutropenia | 100% | NA | NA | NA | NA |
Grade ≥ 3 thrombocytopenia | 100% | NA | NA | NA | NA |
GvHD, any grade | 60% | NA | NA | 0 | NA |